Option chain shows key data for Nuvectis Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nuvectis Pharma.

Nuvectis Pharma (NASDAQ:NVCT) Stock, Option Chain

Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

NVCT

Biotech

News

Health Care

Movers

Trading Ideas

General

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Wall Street

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

ACIU

SOWG

UAVS

VISL

S&amp;P 500 Moves Lower; US Crude Oil Inventories Increase

Oil Price Photo by William Potter on Shutterstock

GXAI

Dow Falls Over 100 Points; US Producer Prices Rise In October

Nuvectis Pharma Inc

Morgan Stanley analyst Meta Marshall maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Equal-Weight and raises the price target from $127 to $132.

Price Target

Analyst Ratings

NTAP

Morgan Stanley Maintains Equal-Weight on NetApp, Raises Price Target to $132

Including Pre-Funded Warrants For Up To 9M Shares,&nbsp;

Offerings

BTAI

BioXcel Therapeutics Prices $7M Public Offering Of 5.6M Shares And Warrants At $0.48 Per Unit; With Proceeds Supporting Neuroscience And Immuno-Oncology Development Efforts

Keybanc analyst Eric Heath maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Overweight and raises the price target from $48 to $57.

RBRK

Keybanc Maintains Overweight on Rubrik, Raises Price Target to $57

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

ANIX

Anixa Biosciences Approves Bitcoin Purchase As Treasury Reserve Asset To Diversify Holdings While Continuing Stock Buyback Program To Enhance Shareholder Value

WIIM

CATO

Cato shares are trading lower after the company announced it will suspend its quarterly dividend, citing economic conditions and sales trends.

Morgan Stanley analyst Keith Weiss maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Overweight and raises the price target from $320 to $375.

ADSK

Morgan Stanley Maintains Overweight on Autodesk, Raises Price Target to $375

SCNI

Scinai Immunotherapeutics shares are trading higher after the company reported a year-over-year increase in Q3 EPS results.

Morgan Stanley analyst Keith Weiss maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Equal-Weight and raises the price target from $685 to $730.

INTU

Morgan Stanley Maintains Equal-Weight on Intuit, Raises Price Target to $730

Gap shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. Also, multiple firms raised their respective price targets.

DXLG

Destination XL Group shares are trading lower after the company reported worse-than-expected Q3 financial results

Cathie Wood, CEO of ARK Invest, has shared her insights on the potential impact of a Trump administration on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and decentralized finance (DeFi). Wood believes that the administration could bring much-needed &#8220;regulatory clarity&#8221; to the fintech sector, particularly if&nbsp;Gary Gensler&nbsp;steps down from his position.
What Happened: During a&nbsp;webinar prerecorded on Nov. 15 and published on Friday, Wood discussed how the Trump administration might influence the digital asset revolution, led by Bitcoin. 
&#8220;If Gary Gensler leaves, that is going to open us up to regulatory clarity and probably, given the Trump administration&#8217;s pronouncements over the last few month, give much more focus on digital asset revolution, broadly led by Bitcoin, which they may put in the Treasury&#8217;s strategic reserve,&#8221; she said.
Wood suggested the possibility of adding Bitcoin to the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121376/strategic-bitcoin-reserve-wouldnt-require-new-taxpayer-dollars-says-sen-cynthia-lummis">U.S. Treasury&#8217;s strategic reserve</a>, given the current circulation of over 19 million Bitcoin and a cap of 21 million. According to Wood, the government might aim to acquire 1 million Bitcoins over time.
Regarding DeFi, Wood highlighted the potential for peer-to-peer lending to remove intermediaries in financial transactions.&nbsp;Yassin Elmandjra, ARK&#8217;s director of digital assets, noted the accelerating&nbsp;trend of using cryptocurrency for&nbsp;commerce, driven by technological and regulatory advancements.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42097462/dogecoin-millionaire-shares-50-million-meme-coin-strategy-for-2025-pepe-brett-are-this-bull-runs-doge-shiba-inu?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Millionaire&#8217; Shares $50 Million Meme Coin Strategy For 2025: Pepe, Brett Are This Bull Run&#8217;s DOGE, Shiba Inu</a>
Elmandjra stressed the importance of governments establishing clear regulations on compliance, tax implications, and consumer protection to enable businesses to navigate the evolving landscape effectively.
Why It Matters: Wood&#8217;s predictions come amidst her ambitious price targets for Bitcoin, including a bull case of $3.8 million if more companies incorporate the cryptocurrency into their balance sheets. However, a recent&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122886/cathie-woods-3-8-million-bitcoin-vision-met-with-doubt-83-say-not-by-2030">Benzinga survey&nbsp;revealed</a> skepticism, with 83% of respondents doubting this target will be met by 2030.
Additionally, ARK Invest has identified an &#8220;uptrend&#8221; in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41352094/cathie-woods-ark-invest-says-uptrend-developing-in-bitcoins-market-structure-because-of-th">Bitcoin&#8217;s market structure</a>, attributed to oversold conditions in the Stablecoin Supply Ratio Oscillator (SSRO). This indicator, which measures Bitcoin&#8217;s potential purchasing power, hit a significant low in September, a level not seen since the 2022 bear market. The SSRO is calculated by dividing Bitcoin&#8217;s supply by the supply of major stablecoins, providing insights into Bitcoin&#8217;s market dynamics.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro,</a> at 8:03 am ET, Bitcoin was trading at $98,764.01, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) at $3,345.98 and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) was at $0.4045. In the past 14 days, post the elections, Bitcoin&#8217;s value experienced 29.9% increase, Ethereum increased by 14.7% and Dogecoin saw a 105.5% hike. 
Meanwhile, ARK 21Shares Bitcoin ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>), which provides exposure to bitcoin which is kept in cold storage was trading only slightly higher at 0.58% during pre-market hours.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42052184/will-shiba-inu-coin-reach-1-cent-by-2025-47-of-benzinga-readers-say?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Will Shiba Inu Coin Reach 1 Cent By 2025? 47% Of Benzinga Readers Say…</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image courtesy: ArkInvest

$DOGE

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Ark Invest's Cathie Wood Says Team Trump Would Give 'Regulatory Clarity' For Bitcoin And Other Digital Assets: '...Which They May Put In The Treasury's Strategic Reserve'

BENF

BEneficient shares are trading higher after the company announced its stockholder equity figure now likely meets Nasdaq's minimum requirement and will regain compliance status.

EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) saw its shares rise in premarket trading on Friday following the announcement of a new share repurchase program.
The company&#8217;s Board of Directors has approved the repurchase of up to $30 million worth of American Depositary Shares (ADSs) or ordinary shares over the next 12 months.
Huazhi Hu, Founder, Chairman, and CEO of EHang, highlighted that the repurchase program reflects the company&#8217;s belief in its future potential and its commitment to delivering value to shareholders.
He emphasized EHang&#8217;s focus on advancing its leadership in providing safe, pilotless, and sustainable electric Vertical Take-Off and Landing (eVTOL) solutions within the rapidly growing Urban Air Mobility (UAM) sector.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger" rel="noreferrer noopener">US Stocks Set To Open Lower On Friday As Investors Eye Cyclical Stocks: Trump&#8217;s Treasury Pick In Focus, Expert Says Case For Fed Pause In December&#8217; Getting Stronger&#8217;</a>
&#8220;Looking ahead, we remain focused on advancing our leadership in providing safe, pilotless, and sustainable eVTOL solutions in the Urban Air Mobility sector, while maintaining a disciplined approach to capital allocation to ensure sustainable growth and profitability,&#8221; Hu said.
In a related development, EHang recently unveiled a new UAM Hub at <a target="_blank" href="https://www.benzinga.com/news/small-cap/24/11/41948048/ehang-expands-evtol-infrastructure-new-uam-hub-powers-up-future-of-autonomous-flights" rel="noreferrer noopener">Luogang Central Park in Hefei, Anhui Province, China</a>.
This marks the second vertiport in the region, following the opening of the UAM Operations Center earlier this year. The Hub is designed to support the operation of EHang&#8217;s EH216-S pilotless passenger drones, which play a central role in the company&#8217;s expanding efforts in the eVTOL market. The new facility, named &#8220;Ascend,&#8221; features a distinctive upward spiral design, symbolizing the growth of the low-altitude economy in the region.
This infrastructure milestone strengthens EHang&#8217;s partnership with Hefei City, helping to advance the commercial use of eVTOL aircraft in Eastern China.
Price Action: EH shares are trading higher by 1.96% to $13.55 premarket at last check Friday.
Image: Shutterstock/ bangoland
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead" target="_blank" rel="noreferrer noopener">Bitcoin&#8217;s Path To $100K &#8216;Inevitable&#8217; But Crypto Community Is &#8216;Leveraged To The Gills,&#8217; Warns Galaxy&#8217;s Mike Novogratz, Predicts Correction To $80K Ahead</a></li>
</ul>

Buybacks

What's Going On With EHang Stock Today?

Morgan Stanley analyst Alex Straton maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Overweight and raises the price target from $29 to $30.

Morgan Stanley Maintains Overweight on Gap, Raises Price Target to $30

A safe, secure, and private way to pay with iPhone and Apple Watch using girocard More customers to benefit from payments with nationwide usability Commerzbank AG announces that customers can use their giro card with Apple Pay - a safe and secure way to pay that helps customers choose contactless payment options with their iPhone or Apple Watch while using the power of the iPhone to protect every transaction.
<a href="https://www.commerzbank.de/group/newsroom/press-releases/applepay-girocard.html" title="https://www.commerzbank.de/group/newsroom/press-releases/applepay-girocard.html">https://www.commerzbank.de/group/newsroom/press-releases/applepay-girocard.html</a>

AAPL

CRZBF

'Commerzbank introduces Apple Pay to its girocard customers' - Commerzbank

Wells Fargo analyst Gary Mobley initiates coverage on Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Equal-Weight rating and announces Price Target of $570.

Initiation

SNPS

Wells Fargo Initiates Coverage On Synopsys with Equal-Weight Rating, Announces Price Target of $570

Morgan Stanley analyst Natasha Bonnet initiates coverage on Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) with a Underweight rating and announces Price Target of $7.2.

Morgan Stanley Initiates Coverage On Ermenegildo Zegna with Underweight Rating, Announces Price Target of $7.2

ESTC

Elastic shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY25 guidance above estimates.

Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) reported quarterly earnings of $0.31 per share. This is a 19.23 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $13.792 million which missed the analyst consensus estimate of $15.150 million by 8.96 percent. This is a 24.27 percent increase over sales of $11.098 million the same period last year.

Earnings Misses

Pyxis Tankers Q3 2024 GAAP EPS $0.31 Up From $0.26 YoY, Sales $13.792M Miss $15.150M Estimate

Tapestry shares are trading higher after the company announced agreements for a $2 billion Accelerated Share Repurchase program.

Nuvectis Pharma reports Q2 results

Nuvectis Pharma (NVCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis fro...

Nuvectis Pharma: Strong Buy Rating on Solid Financials and Promising Oncology Pipeline

Nuvectis gains on FDA's orphan drug designation for cancer therapy

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target...

Nuvectis Pharma (NVCT) Gets a Buy from Roth MKM

Nuvectis Pharma, Inc. ( ($NVCT) ) has released its Q3 earnings. Here is a breakdown of the information Nuvectis Pharma, Inc. presented to its inves...

Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress

Nuvectis Pharma (NVCT) reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovari...

Nuvectis Pharma reports data from Phase 1b study of NXP800

09:46 EST Nuvectis Pharma (NVCT) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

Nuvectis Pharma Inc trading resumes

09:41 EST Nuvectis Pharma (NVCT) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market...

Nuvectis Pharma Inc trading halted, volatility trading pause

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target of $21.00...

Positive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy Rating

Nuvectis sinks after early-stage data for ovarian cancer therapy

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit's Meteoric Rise: Silexion, Nuvectis, Scorpian

Press Releases

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Comments

Nuvectis Pharma

Nuvectis Pharma (NVCT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga